

# In-line 2023 marketing sales



SMRA IJ	BUY
Sector	Property.
Price at 17 Jan 2024 (IDR)	575
Price target (IDR)	700
Upside/Downside (%)	21.7

## Stock Information

PT Summarecon Agung Tbk and its subsidiaries develop and invest in real estate. The Company develops and operates residential houses, apartments, shopping centres, recreational centres and office buildings.

Market cap (IDR bn)	9,493
Shares outstanding (mn)	16,509
52-week range (IDR)	498 - 740
3M average daily vol. ('000)	47,156
3M average daily val. (IDR mn)	27,032

#### Shareholders (%)

Semarop Agung	33.8
Public	66.2

# Stock Performance



Source: Bloomberg

	1M	3M	12M
Performance	2.7	0.9	(0.9)

# Analyst

# Benyamin Mikael

benyamin.mikael@kbvalbury.com

SMRA's 2023 marketing sales came in-line with our expectation of IDR4.5 tn (-8.7% yoy). Further, SMRA aims to achieve a marketing sales target of IDR5.0 tn in 2024, aligning with our expectation of IDR4.95 tn (+10% yoy). SMRA plans to launch several products this year, including new apartment developments in Summarecon Kelapa Gading, the Trevor apartment in Summarecon Serpong, and new housing products in key areas such as Summarecon Serpong, Bogor, Bekasi, Bandung, and Crown Gading. We also saw another mid-term potential growth driver for SMRA after its subsidiary established 2 JV companies with Setiawan Dwi Tunggal. Reiterate BUY on SMRA with DCF-based TP of IDR700 (WACC: 11.2%; LTG: 5%), which implied to 1.1x '24F PB and 82.8% discount to '24F RNAV.

## In-line marketing sales of IDR4.5 tn (-8.7% yoy) in 2023

SMRA's booked IDR1.45 tn of marketing sales in 4Q23 (-0.1% yoy/-0.2% qoq) resulting a IDR4.5 tn of marketing sales (-8.7% yoy) in 2023, in-line with our expectation. In Dec '23, marketing sales surged to IDR826 bn (+3.1% yoy/131.7% mom), contributed by the successful launch of Viola (residential) in Summarecon Crown Gading and Maple (residential) in Summarecon Bogor with total proceeds around IDR320 bn as well as significant contribution from Serpong area of IDR241.8 bn during Summarecon 2023's expo and regular sales.

# Targeting marketing sales of IDR5.0 tn in 2024F (+11% yoy)

SMRA aims to achieve a marketing sales target of IDR5.0 tn in 2024, aligning with our projection of IDR4.95 tn. SMRA plans to launch several products in 2024, including new apartment developments in Summarecon Kelapa Gading, the Trevor apartment in Summarecon Serpong, and new housing products in key areas such as Summarecon Serpong, Bogor, Bekasi, Bandung, and Crown Gading. Additionally, SMRA is well-positioned with an eligible inventory of IDR1.9 tn for the VAT exemption program where IDR1.1 tn of it is residential unit as well as IDR389 bn of shophouse and apartment of IDR364 bn.

# Another mid-term potential growth driver

In mid-Dec'23 SMRA through its subsidiaries, Summarecon Investment Property (SMIP) and Summarecon Property Development (SMPD), established 2 JV companies with Setiawan Dwi Tunggal (SDT). The initial JV, between SMIP and SDT (Surya Selatan Cemerlang), resides in South Tangerang and will engage in the development of apartments, residential properties, and shophouses. Simultaneously, the second JV between SMIP and SDT (Mahakarya Selatan Cemerlang), also located in South Tangerang, focuses on the operation of a shopping mall. Based on our channel check, SDT has notably succeeded in developing "SouthCity", strategically positioned at the convergence of South Jakarta, Cinere, and Pondok Cabe. The establishment of these JV companies serves as another mid-term growth driver for SMRA.


# Undemanding valuation. Reiterate BUY with TP IDR700

We reiterate BUY on SMRA with target price of IDR700 using DCF-based TP (WACC: 11.2%; LTG: 5%), which implied to 1.1x '24F PB and 82.8% discount to '24F RNAV. We still maintain our net profit forecast of IDR1 tn for 2024 (+19.3% yoy). We like SMRA due to 1) undemanding valuation, and 2) strong brand equity, enabling secure project acquisition with minimal capital risk, 3) lower net gearing level. Yet, risks to our call included 1) weak property demand; 2) higher building material cost; 3) stiff competition from the nearby competitor.

Exhibit 1: Key Statistics

Year end Dec (IDR bn)	2021	2022	2023F	2024F	2025F
Revenue	5,568	5,719	6,371	6,869	6,950
EBITDA	1,556	1,712	1,886	2,140	2,089
Net income	324	625	846	1,009	1,002
EPS growth (%)	80.0	93.2	35.2	19.3	(0.6)
PER (x)	29.3	15.2	11.2	9.4	9.5
PBV (x)	1.1	1.0	1.0	0.9	8.0
EV/EBITDA (x)	10.5	8.7	8.5	6.9	6.8
Dividend yield (%)	0.0	1.0	1.2	1.4	1.4
Gearing (x)	0.5	0.3	0.4	0.2	0.1

2027



2026



Exhibit 2: SMRA's Valuation Summary DCF Valuation 2025

DCF valuation	2024	2023	2020	2027	2020
Net Profit	1,009	1,002	1,057	1,197	1,334
Depreciation	246	250	254	259	264
Interest expense (1-tax)	318	290	279	260	242
NWC	(221)	(202)	(210)	(218)	(217)
Capex	(285)	(298)	(311)	(324)	(339)
FCFF	1,067	1,043	1,069	1,174	1,283
Discount factor	1.1	1.2	1.4	1.5	1.7
Discounted Free Cash Flow	959	844	777	767	755
Terminal Value	21,724				
Discounted Terminal Value	12,775				
Enterprise Value	16,878				
Net debt	2,295				
Equity value	14,583				
Minority interest	(3,025)				
12 months forward valuation per share (IDR)	700				

Source: KBVS Research


Exhibit 3: SMRA's Launching Recap

		2023				
Months	Cluster	Location	Unit Sold A	vg Price (bn)	Proceeds	Notes
Mar	Grha Boulevard (Shophouse)	Bogor	54	2.7	150	Sold Out
April	Downtown Drive (Shophouse)	Serpong	76	3.3	250	Sold Out
June	Strozzi (Residential)	Serpong	78	2.2 - 2.5	100	50% take-up rate
July	Genova (Residential)	Bandung	26	Start 2.3	65	59% take-up rate
Aug	Alderwood (Residential)	Bogor	241	Start 1.7	600	Sold Out
Sep	Ruko Gading Boulevard (Shophouse)	Crown Gading	66	Start 3,1	200	87% take-up rate
Oct	Crystal (Shophouse)	Bekasi	48	start 3.4	230	Sold Out
Nov	Sapphire (Shophouse)	Bandung	9	3.8 - 5.4	35	41% take up rate
Dec	Viola (Residential)	Crown Gading	100	start 1.0	150	95% take up rate
	Maple (Residential)	Bogor	40	start 3.9	170	Sold Out




# Summarecon Agung (SMRA)

Exhibit 4: SMRA's marketing sales forecast (IDR bn)




Source: Company, KBVS Research

Exhibit 6: SMRA's marketing sales based on geography (%)




Source: Company, KBVS Research

Exhibit 8: SMRA's payment profile (%)




Source: Company, KBVS Research

Exhibit 5: SMRA's quarterly marketing sales (IDR bn)



Source: Company, KBVS Research


Exhibit 7: SMRA's marketing sales based on product (%)



■ Houses ■ Shoplots ■ Landplots ■ Apartments ■ Office, Commercial

Source: Company, KBVS Research

Exhibit 9: SMRA's net gearing





# FINANCIAL TABLES Exhibit 10: Profit & Loss summary

Profit & Loss (IDR bn)	2021	2022	2023F	2024F	2025F
Revenue	5,568	5,719	6,371	6,869	6,950
Cost of revenue	(2,974)	(2,720)	(3,039)	(3,184)	(3,258)
Gross profit	2,594	3,000	3,333	3,685	3,693
Selling expenses	(515)	(565)	(640)	(690)	(699)
G&A expenses	(733)	(952)	(1,048)	(1,100)	(1,155)
Operating profit	1,345	1,483	1,645	1,894	1,839
EBITDA	1,556	1,712	1,886	2,140	2,089
Other op. income/exp	3	(17)	(19)	(21)	(23)
Finance income	192	157	168	120	145
Finance expense	(1,002)	(857)	(704)	(691)	(668)
Inc/loss from assoc.	8	9	11	11	12
Pre-tax profit	547	775	1,101	1,313	1,305
Tax expense	3	(3)	(17)	(20)	(20)
Minority interest	(226)	(146)	(238)	(285)	(283)
Net profit	324	625	846	1,009	1,002
EPS (IDR)	20	38	51	61	61

Source: Company, KBVS Research

Exhibit 11: Balance sheet

Balance Sheet (IDR bn)	2021	2022	2023F	2024F	2025F
Cash and equivalents	2,774	3,143	2,241	2,713	3,406
Trade receivables	344	376	419	452	457
Inventories	9,254	9,960	10,160	10,360	10,560
Net- Fixed assets	318	370	348	326	301
Other assets	13,360	14,585	15,674	15,937	16,127
Total Assets	26,050	28,434	28,842	29,788	30,851
Trade payables	405	303	338	355	363
Short-term debt + CMLTD	2,919	2,625	2,625	1,925	1,725
Long-term debt	4,120	3,284	3,284	3,083	3,083
Other liabilties	7,376	10,472	9,882	10,596	10,738
Total Liabilities	14,819	16,684	16,129	15,959	15,909
Minority interest	2,569	2,553	2,781	3,025	3,268
Paid capital	1,651	1,651	1,651	1,651	1,651
Retained earnings	7,010	7,547	8,281	9,153	10,022
Other equities	0	0	0	0	0
Total Equity	11,230	11,750	12,713	13,829	14,942



# FINANCIAL TABLES

# Exhibit 12: Profit & Loss summary

Cash Flow (IDR bn)	2021	2022	2023F	2024F	2025F
Net income	324	625	846	1,009	1,002
Depreciation & amortization	211	229	241	246	250
Change in working capital	958	1,825	(1,164)	82	(383)
Cash flow from operations	1,493	2,679	(77)	1,336	870
Capex	(16)	(1,197)	(545)	(295)	(308)
Others	(1)	(50)	61	(60)	(63)
Cash flow from investments	(17)	(1,247)	(484)	(355)	(370)
Changes in debt	(2,413)	(1,130)	-	(901)	(200)
Changes in equity	1,492	-	-	-	-
Dividends paid	-	(99)	(115)	(137)	(136)
Others	98	(7)	233	244	247
Cash flow from financing	(822)	(1,236)	118	(794)	(90)
Net Cash Flow	654	196	(443)	187	410

Source: Company, KBVS Research

Exhibit 13: Cash flow

Key Ratios (%)	2021	2022	2023F	2024F	2025F
Revenue growth	10.7	13.7	11.4	7.8	1.2
EBIT growth	25.3	10.2	10.9	15.2	(2.9)
EBITDA growth	108.8	129.6	10.2	13.4	(2.4)
Net profit growth	80.0	93.2	35.2	19.3	-0.6
Gross margin	46.6	52.4	52.3	53.6	53.1
EBIT margin	24.2	25.9	25.8	27.6	26.5
EBITDA margin	28.0	29.9	29.6	31.1	30.1
Net margin	5.8	10.9	13.3	14.7	14.4
ROA	1.3	2.3	3.0	3.4	3.3
ROE	4.2	7.8	8.8	9.7	8.9
Net gearing (x)	0.5	0.3	0.4	0.2	0.1
Net debt/EBITDA (x)	2.4	1.6	1.9	0.0	0.0
Interest coverage ratio (x)	1.9	2.4	3.5	3.7	4.0



#### Disclaimer

This report is prepared by PT KB Valbury Sekuritas, a member of the Indonesia Stock Exchange, or its subsidiaries or its affiliates ("KBVS"). All the material presented in this report is under copyright to KBVS. None of the parts of this material, nor its contents, may be copied, photocopied, or duplicated in any form or by any means or altered in any way, or transmitted to, or distributed to any other party without the prior written consent of KBVS.

The research presented in this report is based on the information obtained by KBVS from sources believed to be reliable, however KBVS do not make representations as to their accuracy, completeness or correctness. KBVS accepts no liability for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from the use of the material presented in this report and further communication given or relied in relation to this document. The material in this report is not to be construed as an offer or a solicitation of an offer to buy or sell any securities or financial products. This report is not to be relied upon in substitution for the exercise of independent judgement. Past performance and no representation or warranty, express or implied, is made regarding future performance. Information, valuations, opinions, forecasts and estimates contained in this report reflects a judgement at its original date of publication by KBVS and are subject to change without notice, its accuracy is not guaranteed or it may be incomplete.

The Research Analyst(s) primarily responsible for the content of this research report, in part or as a whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The Analyst also certifies that no part of his/her compensation was, is or will related to specific recommendation views expressed in this report. It also certifies that the views and recommendations expressed in this report do not and will not take into account client circumstances, objectives, needs and no intentions involved as a use for recommendations for sale or buy any securities or financial instruments.



Sahid Sudirman Center 41<sup>th</sup> Floor Unit A–C Jalan Jenderal Sudirman No. 86 Kelurahan Karet Tengsin, Kecamatan Tanah Abang, Jakarta Pusat 10220, Indonesia T. +62 21 – 250 98 300

# **Branch Office**

# Jakarta – Sudirman

Sahid Sudirman Center 41st Floor Unit A-C Jalan Jenderal Sudirman No. 86 Karet Tengsin, Tanah Abang, Jakarta Pusat 10220 T. (021) 25098300/301

# Bandung

Jl, HOS Cokroaminoto No, 82 Bandung 40171 T. (022) 87255800

# Palembang

Komplek PTC Mall Blok I No. 7 Jl. R. Sukamto Palembang 30114 T. (0711) 5700281

# Semarang

Candi Plaza Building Lt. Dasar Jl. Sultan Agung No. 90–90A Semarang 50252 T. (024) 8501122

# Jakarta - Kelapa Gading

Rukan Plaza Pasifik Jl, Raya Boulevard Barat Blok A1 No. 10 Jakarta Utara 11620 T. (021) 29451577

# Malang

Jl. Pahlawan Trip No. 7 Malang 65112 T. (0341) 585888

# Surabaya

Pakuwon Center Lt 21 Jl, Embong Malang No.1 Surabaya 60261 T. (031) 2955788

# Makassar

Komplek RUKO Citraland City Losari Business Park, Blok B2 No. 09 Jl. Citraland Boulevard Makassar 90111 T. (0241) 16000818

# Jakarta - Puri Indah

Rukan Grand Aries Niaga Blok E1 No. IV Jl. Taman Aries, Kembangan Jakarta Barat 11620 T. (021) 22542390

# Banjarmasin

Jl. Gatot Subroto No. 33 Banjarmasin 70235 T. (0511) - 3265918

# Padang

Jl. Kampung Nias II No. 10, Padang 25211 T. (0751) 8955747

# Medan

Komplek Jati Junction No, P5-5A Jl. Perintis Kemerdekaan Medan 20218 T. (061) 88816222

# Jakarta – Pluit

Jl. Pluit Putra Raya No. 2 Jakarta Utara 14450 T. (021) 6692119

# Pekanbaru

Jl. Tuanku Tambusai, Komplek CNN Blok A No. 3 Pekanbaru 28291 T. (0761) 839393

# Yogyakarta

Jl, Magelang KM 5.5 No. 75 Yogyakarta 55000 T. (0274) 623111

# Denpasar

JI, Teuku Umar No, 177 Komplek Ibis Styles Hotel Denpasar Bali 80114 T. (0361) 225229

# **Investment Gallery**

# Jakart

Citra Garden 6 Ruko Sixth Avenue Blok J.1 A/18, Cengkareng Jakarta Barat 11820 T. (021) 522392181

# Semarang

Jl, MT Haryono 637 Semarang 50242 T. (024) 8415195

# Salatiga

Jl. Diponegoro No. 68 Salatiga 50711 T. (0298) 313007

# Solo

Jl. Ronggowarsito No. 34 Surakarta 57118 T. (0271) 6726306

